Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorRuijin Hospital

About this trial

The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.

The main purposes of this study are:

1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China; 2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years old.

Meets the clinical diagnostic criteria for HAP in the 2018 HAP/VAP guidelines. Chest X-ray or CT shows new or progressive infiltrative shadows, consolidation shadows, or ground glass shadows, combined with 2 or more of the following 3 clinical symptoms, to establish a clinical diagnosis: 1) Fever, body temperature>38 ℃; 2) Purulent airway secretions; 3) Peripheral blood white blood cell count >10 × 10^9/L or <4 × 10^9/L.

Having qualified evidence of responsible pathogen. On the basis of clinical diagnosis, one of the following conditions should be met simultaneously: 1) Qualified lower respiratory tract secretions (neutrophil count >25/low magnification field, epithelial cell count <10/low magnification field, or a ratio of the two >2.5:1), pathogenic bacteria cultured through bronchoscopy anti pollution brush (PSB), bronchoalveolar lavage fluid (BALF), lung tissue or sterile body fluid, and consistent with clinical manifestations; 2) Pathology, cytopathology, or direct microscopic examination of lung tissue specimens showing fungi and evidence of tissue damage; 3) The serum IgM antibodies of atypical pathogens or viruses change from negative to positive, or the titers of specific IgG antibodies in both acute and recovery phases show a 4-fold or more change. During the outbreak of respiratory viruses and with a history of epidemiological contact, respiratory secretions were tested positive for corresponding virus antigens, nucleic acid tests, or virus culture.

obtained informed consent

Disqualifiers

Those who cannot understand and execute the investigation plan.

Active pulmonary tuberculosis;

Severely immunosuppressed patients: absolute neutrophil count <0.5× 10^9/L, CD4<200/ml.

Trial population

hospital-acquired pneumonia adult patients with qualified evidence of responsible pathogen in China

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • prognosis status

    Other intervention

    observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28

Treatment groups

4,000 Participants
are divided into 2 treatment groups
Group A: survival group1 intervention
Group B: mortality group1 intervention

Trial outcomes

Primary outcomes

1

mortality at day 28

prognosis

Time frame
28 days after enrollment

Secondary outcomes

1

clinical characteristics

symptoms, physical examinations, comorbidity, laboratory tests, imaging findings and treatment

Time frame
0 day, 3 days, 7days, 14 days and 28 days after enrollment
2

pathogen

molecular characteristics of responsible pathogen; antibiotic resistance of bacteria

Time frame
0 day, 3 days, 7days, 14 days and 28 days after enrollment

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: